Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Recreational use of ketamine"'
Publikováno v:
Clinical Toxicology. 59:528-531
Dear Editor, The recreational use of ketamine analogues, a group of new psychoactive substances (NPS), is evolving worldwide [1,2]. We describe 13 cases of emergency department (ED) admissions in T...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87f98033ba7bf5bec19db7a0c41b2e4d
https://doi.org/10.1080/15563650.2020.1826506
https://doi.org/10.1080/15563650.2020.1826506
Autor:
Kyoung-Sae Na, Yong Ku Kim
Publikováno v:
Progress in neuro-psychopharmacologybiological psychiatry. 104
Ketamine was initially used as an anesthetic which could induce cognitive impairment and psychomimetic effects. In initial randomized controlled trials (RCTs) that mostly included a small sample size and were investigator-initiated, ketamine reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37228d85fe555bcce95053b1e3b396fa
https://pubmed.ncbi.nlm.nih.gov/32777326
https://pubmed.ncbi.nlm.nih.gov/32777326
Publikováno v:
BMC Public Health, Vol 19, Iss 1, Pp 1-13 (2019)
BMC Public Health
BMC Public Health
Background The popularity of ketamine for recreational use has been increasing in Asia, including Taiwan. Still, little known about the pattern of ketamine expectancies and whether such patterns are related to ketamine use. This study aimed to examin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e99dd50e334aac52dad96773b8f76eb8
https://doi.org/10.1186/s12889-019-7616-1
https://doi.org/10.1186/s12889-019-7616-1
Publikováno v:
Journal of Psychoactive Drugs. 48:86-92
Despite the rise in recreational use of ketamine in Malaysia, there have been no studies of users or of the health-related consequences they face. This study was initiated to examine ketamine use and its health consequences. A structured questionnair
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cef8685b66e4102d21660183a3ca4cd8
https://doi.org/10.1080/02791072.2016.1156790
https://doi.org/10.1080/02791072.2016.1156790
Autor:
Taiana Cristina Vilhena Sarmento Carvalheiro, Enéas Andrade Fontes-Júnior, Antônio Rafael Quadros Gomes, Ricardo Sousa de Oliveira Paraense, Cristiane Socorro Ferraz Maia, Rui Daniel Prediger, Marta Chagas Monteiro, Rafael Rodrigues Lima, Maria Elena Crespo-Lopez, Luanna Melo Pereira Fernandes, Sabrina C. Cartágenes, Thais Miranda de Sousa
Publikováno v:
Oxidative Medicine and Cellular Longevity
Oxidative Medicine and Cellular Longevity, Vol 2019 (2019)
Oxidative Medicine and Cellular Longevity, Vol 2019 (2019)
Ketamine is used in clinical practice as an anesthetic that pharmacologically modulates neurotransmission in postsynaptic receptors, such as NMDA receptors. However, widespread recreational use of ketamine in “party drug” worldwide since the 1990
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc28f1c6ddb6e9829282e00f10efb35f
https://pubmed.ncbi.nlm.nih.gov/31001375
https://pubmed.ncbi.nlm.nih.gov/31001375
Autor:
E. Fontes de Andrade, Rui Daniel Prediger, Sabrina C. Cartágenes, C.S.F. Maia, Luanna Melo Pereira Fernandes
Ketamine acts as an N-methyl- d -aspartate (NMDA) receptor antagonist that was originally synthesized for use as a dissociative anesthetic, and remains widely used for this clinical application. More recently, the recreational use of ketamine, partic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b92904b49a6d38f52eddfbcc3b2496f
https://doi.org/10.1016/b978-0-12-805373-7.00032-3
https://doi.org/10.1016/b978-0-12-805373-7.00032-3
Autor:
Robert H. Lipsky, Ke Xu
Publikováno v:
Experimental Biology and Medicine. 240:145-155
For more than 40 years following its approval by the Food and Drug Administration (FDA) as an anesthetic, ketamine, a non-competitive N-methyl-d-aspartic acid (NMDA) receptor antagonist, has been used as a tool of psychiatric research. As a psychedel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0486deff541de3bff7bad1d174225277
https://doi.org/10.1177/1535370214549531
https://doi.org/10.1177/1535370214549531
Publikováno v:
British Journal of Clinical Pharmacology. 77:357-367
The anaesthetic ketamine is used to treat various chronic pain syndromes, especially those that have a neuropathic component. Low dose ketamine produces strong analgesia in neuropathic pain states, presumably by inhibition of the N-methyl-D-aspartate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b669707b4267e79f64e177f9d154df79
https://doi.org/10.1111/bcp.12094
https://doi.org/10.1111/bcp.12094
Publikováno v:
The primary care companion for CNS disorders. 18(3)
To the Editor: Ketamine, an NMDA (N-methyl-d-aspartate) glutamate antagonist, commonly used as an anesthetic agent, has emerged as a major substance of abuse particularly in Asia.1 Here, we present, to our knowledge, the first case of a patient who d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a19b9b41fb6a79884021b5b69b4e2c5
https://pubmed.ncbi.nlm.nih.gov/27722024
https://pubmed.ncbi.nlm.nih.gov/27722024
Ketamine was first synthesized in the early 1960s for use as an anesthetic and analgesic by noncompetitive antagonism of the N-methyl- d -aspartate receptor. However, the induction of unusual and substantial changes in perception and emotion (psyched
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ea1b9c9b4472fe5572c29846df6ebbc
https://doi.org/10.1016/b978-0-12-800212-4.00062-5
https://doi.org/10.1016/b978-0-12-800212-4.00062-5